1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 22nd April 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Prevalence and Risk Factors of de Novo Widespread Post-COVID Pain in Non-Hospitalized COVID-19 Survivors, 2023, Ebbesen et al.

Discussion in 'Long Covid research' started by SNT Gatchaman, Aug 27, 2023.

  1. SNT Gatchaman

    SNT Gatchaman Senior Member (Voting Rights)

    Messages:
    4,481
    Location:
    Aotearoa New Zealand
    Prevalence and Risk Factors of de Novo Widespread Post-COVID Pain in Non-Hospitalized COVID-19 Survivors: A Nation-Wide Exploratory Population-Based Survey
    Brian D. Ebbesen; Rocco Giordano; Juan Antonio Valera-Calero; Jakob Nebeling Hedegaard; César Fernández-de-las-Peñas; Lars Arendt-Nielsen

    This survey investigated the prevalence of de novo widespread musculoskeletal post-COVID pain and risk factors for its development in non-hospitalized COVID-19 survivors. A nationwide exploratory cross-sectional study was conducted including a cohort of 593,741 Danish residents that had suffered from a SARS-CoV-2 infection from March 2020 to December 2021. A questionnaire was distributed to the Danish population via digital mail system (e-Boks). Self-reported demographic data, previous medical comorbidities (diagnosed), socioeconomic data, time of infection, prior chronic pain conditions (diagnosed), development of de novo widespread pain after infection, pain medication, and pain intensity information were collected.

    Responders consisted of 130,443 non-hospitalized participants (58.2% women; mean age: 50.2 years). At a mean of 14.4 (SD 6.0) months after infection, 6,875 (5.3%) patients reported the presence of de novo widespread musculoskeletal post-COVID pain. Almost 75% of the patients reported a moderate to severe intensity of the pain. In conclusion, de novo widespread post-COVID pain was present in 5.3% of non-hospitalized COVID-19 survivors one year after infection (14.4±6.0 months). Older age, female sex, higher body mass index, and history of migraine, whiplash, stress, type-2 diabetes, neurological disorders, and lower socioeconomic status, were risk factors associated with the development of de novo widespread post-COVID pain in non-hospitalized patients.

    As de novo widespread pain is considered a sign of sensitization, this group will require specialized pain management attention.

    Link | PDF (The Journal of Pain)
     
    Hutan likes this.

Share This Page